@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix go: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix hasAgent: . @prefix hasPart: . @prefix ProteinComplex: . @prefix pfh: . @prefix species: . @prefix occursIn: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasAgent: sub:_2; a go:0003824 . sub:_2 geneProductOf: hgnc:9053; a Protein: . sub:_3 hasPart: sub:_4, sub:_5; a ProteinComplex: . sub:_4 geneProductOf: hgnc:6150; a Protein: . sub:_5 geneProductOf: hgnc:6160; a Protein: . sub:_6 hasAgent: sub:_7; a go:0016301 . sub:_7 geneProductOf: pfh:PRKC%20Family; a Protein: . sub:_8 rdf:object sub:_6; rdf:predicate belv:increases; rdf:subject sub:_3; a rdf:Statement . sub:_9 occursIn: species:9606; rdf:object sub:_8; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "cat(p(HGNC:PLAUR)) -> (complex(p(HGNC:ITGAV),p(HGNC:ITGB5)) -> kin(p(PFH:\"PRKC Family\")))", "complex(p(HGNC:ITGAV),p(HGNC:ITGB5)) -> kin(p(PFH:\"PRKC Family\"))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_12; pav:version "1.4" . sub:_10 dce:identifier "Landes Bioscience - Altered Integrin Expression in Three Common Types of Human Cancer=Breast Cancer"; dce:title "Landes Bioscience - Altered Integrin Expression in Three Common Types of Human Cancer=Breast Cancer"; dce:type "Other" . sub:_11 prov:value "The expression of a6b4 integrin may also inhibit malignant properties of breast cancer cells by inducing apoptosis via activation of p53. However, the expression of this integrin may facilitate carcinoma progression if p53 is in a mutated, inactive form. 85 , 86 It has also been suggested that integrin a6b4-mediated invasion occurs through PI3-kinase signalling. 87 In human breast cancer, integrin aVb3 has been found in both active and inactive forms. It has been proposed that the active form promotes metastatic capability via interaction with platelets. 88 In one experimental mouse model, the metastatic capacity of human breast cancer cells has been reduced by using the snake venom disintegrin, contortrostatin, which can bind to aVb3 integrin. 89 Another vitronectin receptor, aVb5, has also been found to have a role in the invasion process. Some results indicate that aVb5-dependent breast cancer cell migration may be partly regulated by urokinase. Urokinase receptor (uPAR) can interact with aVb5 and aVb1 integrins, and aVb5-mediated cytoskeletal rearrangement and activation of protein kinase C occurs in response to urokinase."; prov:wasQuotedFrom sub:_10 . sub:_12 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource sub:_10; prov:wasDerivedFrom beldoc:, sub:_11 . } sub:pubinfo { this: dct:created "2014-07-03T14:29:42.041+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }